NICE Guidance UPDATE on Neuropathic Pain – Pharmacological Management (CG173)
This clinical guideline updates and replaces previous guidance (CG96), and makes recommendations regarding the medication for treating neuropathic or “nerve” pain.
The incidence of painful diabetic neuropathy affects between 16% – 26% of diabetics; post-hepatic neuralgia affects 8%-19% of patients who have had Shingles; and 6%-8% of chronic pain is believed to be neuropathic.
Commonly used pharmacological treatments include antidepressants (tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors [SSRIs] and serotonin–norepinephrine reuptake inhibitors [SNRIs]), antiepileptic drugs, topical treatments and opioid analgesics.
Combinations of these drugs are often used in practice, and recommendations for which drugs should and shouldn’t be used are provided in the guidelines.
For more information:
Photo by LadyofHats Mariana Ruiz Villarreal (i did it myself) [Public domain], via Wikimedia Commons